Press Releases April 14, 2026 08:00 PM

BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026

BillionToOne to announce Q1 2026 financial results on May 6, 2026, with a follow-up conference call scheduled

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
BLLN

BillionToOne, a molecular diagnostics company traded on NASDAQ under the ticker BLLN, will release its financial results for the first quarter of 2026 on May 6, 2026, followed by a conference call to discuss the results. The company specializes in advanced DNA molecular counting technology aimed at creating accessible, powerful diagnostic tests.

BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026
BLLN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • BillionToOne plans to report its Q1 2026 financial results on May 6, 2026 after market close.
  • A conference call to discuss these results is scheduled the same day to provide insights to investors and analysts.
  • The company is focused on molecular diagnostics, specifically its patented Quantitative Counting Templates technology which enables precise DNA molecule counting at the single-molecule level.

MENLO PARK, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, May 6, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.

Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested listeners will be available on the “Events” page of BillionToOne’s investor relations website at https://investors.billiontoone.com/.

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, visit www.billiontoone.com.

Investor Contact
[email protected]

Media Contact
[email protected]


Risks

  • Financial results may not meet market expectations, causing potential stock price volatility.
  • Dependence on successful commercialization of patented technology in a competitive molecular diagnostics sector.
  • Uncertainties related to regulatory approvals and adoption of new diagnostic tests that could impact revenue growth.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026